Covalon Technologies (COV) Q2 2026 earnings summary

Executive summary

• Q2 revenue grew nearly 15% year-over-year to $8.7 million, driven by robust growth in U.S. vascular access, surgical consumables, and advanced wound care channels.

• Gross margin improved to 61.5%, with adjusted EBITDA more than doubling year-over-year to $1.3 million.

• Diluted EPS rose to $0.04 from $0.02 year-over-year, and net income increased 155% to $1.1 million.

• Significant momentum in contamination prevention, with rapid adoption of VALGuard and CovaClear products by major U.S. hospitals and strong clinical validation.

• Operating expenses increased 15% year-over-year in Q2, mainly due to regulatory and operational investments.

Financial highlights

• Q2 revenue: $8.7 million, up 14.9% year-over-year; gross profit: $5.4 million, up 30%; gross margin: 61.5%.

• Adjusted EBITDA: $1.3 million, up 127% year-over-year; adjusted gross margin: 62.9%.

• Diluted EPS: $0.04 vs. $0.02 last year; net income: $1.1 million, up 155%.

• Year-to-date revenue: $15.6 million, flat year-over-year; gross margin YTD at 60%.

• Cash position at quarter-end: $16.6 million, with no bank debt.

Outlook and guidance

• Strong second half expected, with Q3 and Q4 projected to outperform the first half across all sales channels.

• Management remains bullish on achieving and potentially exceeding $20–30 million in vascular access revenue by 2030.

• Gross margin guidance in the 55–65% range, with high 50s to low 60s considered outstanding for the company’s scale.

• Robust pipeline for CovaClear and VALGuard, with expectations for continued strong adoption and further hospital penetration.